Exidavnemab

Exidavnemab is BioArctic's anti-aggregated α-synuclein antibody in Phase 2a testing for Parkinson's disease and multiple system atrophy (NCT06671938, the EXIST study), a 38-patient safety/PK trial that is ACTIVE_NOT_RECRUITING [1][2]. FDA granted orphan drug designation for MSA in March 2025 [7]. BioArctic built its reputation on lecanemab (Leqembi), the first anti-amyloid antibody to receive traditional FDA approval based on demonstrated slowing of clinical decline - explicitly distinct from aducanumab's contested 2021 accelerated approval - and is applying the same selective-aggregate-binding playbook to synuclein. The space has produced two outright Phase 2 misses and one statistically negative-but-directionally-positive Phase 2b (PADOVA, December 2024), so a clean pharmacodynamic readout here would be a meaningful signal in a field defined by disappointment [4][8].

Novel compound, Phase 2a, FDA orphan drug designation for MSA (March 2025) [7]. The Phase 1 single-ascending-dose study in healthy Western, Japanese, and Han Chinese adults (Boström et al., J Clin Pharmacol 2024) reported acceptable tolerability and dose-proportional PK with a half-life consistent with monthly or less-frequent IV dosing [1]. The EXIST Phase 2a trial (NCT06671938) is ACTIVE_NOT_RECRUITING, with 38 patients split between Parkinson's and MSA at Swedish and other European sites, primary endpoint AEs/SAEs measured through day 176; first patient was dosed 5 December 2024 [2][9]. ClinicalTrials.gov does not list a public primary completion date as of writeup generation (2026-06-02) - given the day-176 window and the December 2024 first dose, plus the later MSA expansion cohort, topline likely lands in 2026-H2; this should be re-checked against the registry before publication. Next meaningful catalyst is the Phase 2a safety/PK package plus any exploratory biomarker data BioArctic chooses to release. The strategic decision after that is Phase 2b efficacy design and almost certainly a partnership - BioArctic (Nasdaq Stockholm Large Cap: BIOA B, market cap ~SEK 29B / ~$2.9B as of mid-2026 [10]) is supported by lecanemab royalties from Eisai, not by capacity to fund a multi-hundred-million-dollar Phase 3 in neurodegeneration alone.

α-synuclein is a protein crammed into nerve-cell synapses where it helps package and release neurotransmitters - the chemical signals neurons use to talk to each other [3]. In Parkinson's and MSA, α-synuclein misfolds and clumps into toxic aggregates (the Lewy bodies pathologists find in autopsied PD brains), and those aggregates appear to drive the death of dopamine neurons in the substantia nigra. Exidavnemab is engineered to bind selectively to the aggregated, toxic forms while leaving normal monomeric α-synuclein alone - the same conformation-selective design BioArctic used with lecanemab against amyloid protofibrils. The genetic case is strong: SNCA point mutations and gene duplications cause familial PD, and Open Targets scores hereditary late-onset PD at 0.80 evidence. The therapeutic case is weaker. Prasinezumab (Roche/Prothena), the most advanced anti-synuclein antibody, missed its PASADENA Phase 2 primary endpoint but showed motor signals in pre-specified subgroups [4]; the larger PADOVA Phase 2b read out 18 December 2024 and also missed (HR 0.84, p=0.0657 on time to confirmed motor progression), though levodopa-treated subgroup signals (HR 0.79, nominal p=0.0431) and other secondary trends prompted Roche to advance to Phase 3 in June 2025 [8]. Cinpanemab (Biogen) failed cleanly in the SPARK trial (Lang et al., NEJM 2022) and was discontinued [5]. Target validation is real; clinical translation is unproven.

NCT06671938 (EXIST) is a multi-center, randomized, double-blind, placebo-controlled multiple-ascending-dose Phase 2a in 38 patients with Parkinson's disease and multiple system atrophy, sponsored by BioArctic AB [2]. Primary endpoint is the number of participants with AEs and SAEs over the dosing period through day 176. This is a safety/tolerability/PK study, not powered to detect clinical efficacy. What to actually watch in this readout: CSF (cerebrospinal fluid, sampled by lumbar puncture) and plasma pharmacodynamic markers showing target engagement (free vs. bound α-synuclein, aggregate-specific assays); exploratory imaging endpoints if included - DAT-SPECT (a brain scan measuring dopamine-transporter density, used as a proxy for surviving dopamine neurons); skin biopsy α-synuclein via RT-QuIC (an ultrasensitive seed-amplification assay that detects misfolded protein in tissue or fluid); and any directional signal in MDS-UPDRS motor scores (the standardized Movement Disorder Society Unified Parkinson's Disease Rating Scale, ~0-260 points, with the motor sub-scale most relevant here) despite the trial being underpowered to detect it. The MSA arm is the more interesting half - MSA progresses two to three times faster than PD, so a 6-12 month treatment window has a better chance of revealing a clinical signature. Lundbeck's AMULET Phase 2 of Lu AF82422 in MSA is the most direct competitive read-across. Sample size is small and primary endpoint is safety, so a positive readout here is necessary but nowhere near sufficient for go/no-go on a registration program.

Most drugs that enter Phase 2 never reach approval, and our model estimates this one has a 3% chance of eventually getting there. That starting point comes from the historical approval rate for Phase 2 drugs in this area, which is about 24%, then adjusted based on ten specific facts about this trial and its sponsor. The estimate falls well below the baseline mainly because of heavier-than-usual blinding, the sponsor's thin or weak approval track record, weak earlier-phase results, and a randomized trial design. The remaining factors were close to average for this stage, so they didn't move the number much either way.

Efficacy risk dominates everything else. Two completed Phase 2 readouts in this class (PASADENA, SPARK) failed their primary endpoints and PADOVA Phase 2b also missed in 2024 [4][5][8]. The biology may be correct while the therapeutic window - enough brain-penetrant antibody to clear enough aggregated α-synuclein to slow neurodegeneration - may simply not exist for a peripherally dosed IgG. Patient selection is the other axis: by the time PD is clinically diagnosed, roughly 60% of substantia nigra dopamine neurons are already dead, so disease modification likely requires biomarker-stratified prodromal (pre-symptomatic, pre-diagnosis) populations that don't yet have established trial infrastructure. Safety risk is moderate. Anti-amyloid antibodies (lecanemab, donanemab) carry ARIA - amyloid-related imaging abnormalities including brain edema and microhemorrhage - and whether anti-synuclein antibodies will produce an analogous on-target neuroimaging finding is unknown. Phase 1 was clean but small-n studies don't surface rare events. Execution risk: BioArctic is small (~SEK 29B market cap), lecanemab royalties are the main revenue line (Q2-Q4 2025 royalties from Eisai totaled ~SEK 407M; full year 2025 operating profit >SEK 1.2B [11][12]), and Phase 3 in PD or MSA will require a partner. The natural partner story is more complicated than it looks: AbbVie originally licensed BioArctic's α-synuclein portfolio (including ABBV-0805/BAN0805, the same molecule as exidavnemab) in 2018 and terminated the deal in April 2022, returning rights to BioArctic [13]. Eisai's relationship with BioArctic is around Alzheimer's (lecanemab, BAN2802); no public right-of-first-negotiation on synuclein assets has been disclosed - treat as unknown. Commercial risk is real even on approval: payers are already pushing back on lecanemab's ~$26,500/year list, and an anti-synuclein product would face the same friction in a PD market where levodopa generics cost pennies per dose.

Worth watching, low expected value. The specific signal that would matter from the Phase 2a topline: clear pharmacodynamic target engagement in CSF/plasma α-synuclein assays AND a clinical hint in the MSA arm where progression speed makes a 6-12 month signal detectable. If both show, this becomes a real Phase 2b candidate and BioArctic likely lands a partnership at meaningful economics - but note that the obvious historical partner (AbbVie) already walked from this exact molecule in 2022, and Eisai's collaboration scope has been Alzheimer's, not synuclein. If engagement looks good but clinical is flat, it's the prasinezumab story again: biology says yes, clinical says maybe, you raise capital and run a bigger trial on subgroup hope. If safety is fine but engagement is weak, the program effectively dies and the broader antibody-against-synuclein thesis takes another hit. Check back when BioArctic announces Phase 2a topline, likely 2026-H2 - verify against the NCT06671938 registry entry before relying on this writeup. The deeper question for the field isn't about exidavnemab specifically - it's whether any peripherally dosed antibody can shift synuclein pathology enough to change PD or MSA outcomes. If the answer continues to look like no, the live bets shift to small-molecule aggregation inhibitors (UCB's minzasolmin) and SNCA-directed antisense oligonucleotides, not next-generation antibodies.